---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Indication questions"
description: "Indication questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Eligibility. Questions: What is Verzenio approved for in early breast cancer? What does high risk of recurrence mean for Verzenio in early breast cancer? Is Verzenio approved for monarchE Cohort 2 patients selected by Ki-67 score? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Indication questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Indication questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications: Indication](https://www.evicenter.com/medical-information/verzenio/indication).

## Indication

<a id="verzenio-indication"></a>

### What is Verzenio approved for in early breast cancer?

> “VERZENIO® (abemaciclib) is indicated:
>
> in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=VERZENIO%C2%AE%20%28abemaciclib%29%20is%20indicated%3A,at%20high%20risk%20of%20recurrence.)

## Eligibility

<a id="verzenio-high-risk-definition"></a>

### What does high risk of recurrence mean for Verzenio in early breast cancer?

> “<sup>a</sup>High-risk was defined as HR+, HER2– EBC with either ≥4 positive nodes, OR 1-3 positive nodes and tumors that were ≥5 cm, histological Grade 3—or both<sup>3</sup>”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=was%20defined%20as%20HR%2B%2C%20HER2%E2%80%93,%E2%89%A55%20cm%2C%20histological%20Grade%203%E2%80%94or)

> “To be enrolled, patients had to have HR-positive HER2-negative early breast cancer with tumor involvement in at least 1 axillary lymph node (pALN) and to be enrolled in cohort 1 had to have either:
>
> ≥4 pALN or
> 1-3 pALN and at least one of:
> tumor grade 3 or
> tumor size ≥50 mm”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=To%20be%20enrolled%2C%20patients%20had,tumor%20size%20%E2%89%A550%20mm)

<a id="verzenio-cohort-2-ki67"></a>

### Is Verzenio approved for monarchE Cohort 2 patients selected by Ki-67 score?

> “To be enrolled in Cohort 2 (n=517), patients had to have 1-3 positive nodes and Ki-67 score ≥20%.”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=To%20be%20enrolled%20in%20Cohort%202,nodes%20and%20Ki%2D67%20score%20%E2%89%A520%25.)

> “Patients enrolled in cohort 2 could not have met the eligibility criteria for cohort 1.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Patients%20enrolled%20in%20cohort%202,eligibility%20criteria%20for%20cohort%201.)

> “Verzenio is approved for use in Cohort 1 (91% of the ITT population)<sup>3</sup>”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=Verzenio%20is%20approved%20for%20use%20in%20Cohort%201%20%2891%25%20of%20the%20ITT)

> “A statistically significant difference in IDFS was observed in the ITT population, which was primarily attributed to the patients treated in Cohort 1.<sup>3,5</sup> While the OS data in Cohort 2 remains immature, more deaths were observed among those receiving Verzenio plus standard endocrine therapy compared to those receiving standard endocrine therapy alone (10/253 vs 5/264).<sup>3</sup>”

Source: [VERZENIO: Verzenio® + ET for Early Breast Cancer | Efficacy, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer#:~:text=A%20statistically%20significant%20difference%20in,endocrine%20therapy%20alone%20%2810%2F253%20vs)

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Clinical trials](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines)
